Unknown

Dataset Information

0

Screening for potent and selective anticlostridial leads among FDA-approved drugs.


ABSTRACT: Clostridium difficile is a leading cause of morbidity and mortality particularly in hospital settings. In addition, treatment is very challenging due to the scarcity of effective therapeutic options. Thus, there remains an unmet need to identify new therapeutic agents capable of treating C. difficile infections. In the current study, we screened two FDA-approved drug libraries against C. difficile. Out of almost 3200 drugs screened, 50 drugs were capable of inhibiting the growth of C. difficile. Remarkably, some of the potent inhibitors have never been reported before and showed activity in a clinically achievable range. Structure-activity relationship analysis of the active hits clustered the potent inhibitors into four chemical groups; nitroimidazoles (MIC50?=?0.06-2.7??M), salicylanilides (MIC50?=?0.2-0.6??M), imidazole antifungals (MIC50?=?4.8-11.6??M), and miscellaneous group (MIC50?=?0.4-22.2??M). The most potent drugs from the initial screening were further evaluated against additional clinically relevant strains of C. difficile. Moreover, we tested the activity of potent inhibitors against representative strains of human normal gut microbiota to investigate the selectivity of the inhibitors towards C. difficile. Overall, this study provides a platform that could be used for further development of potent and selective anticlostridial antibiotics.

SUBMITTER: AbdelKhalek A 

PROVIDER: S-EPMC7211121 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Screening for potent and selective anticlostridial leads among FDA-approved drugs.

AbdelKhalek Ahmed A   Mohammad Haroon H   Mayhoub Abdelrahman S AS   Seleem Mohamed N MN  

The Journal of antibiotics 20200304 6


Clostridium difficile is a leading cause of morbidity and mortality particularly in hospital settings. In addition, treatment is very challenging due to the scarcity of effective therapeutic options. Thus, there remains an unmet need to identify new therapeutic agents capable of treating C. difficile infections. In the current study, we screened two FDA-approved drug libraries against C. difficile. Out of almost 3200 drugs screened, 50 drugs were capable of inhibiting the growth of C. difficile.  ...[more]

Similar Datasets

| S-EPMC8475441 | biostudies-literature
| S-EPMC4102417 | biostudies-literature
| S-EPMC8014887 | biostudies-literature
| S-EPMC5640845 | biostudies-literature
| S-EPMC9705369 | biostudies-literature
| S-EPMC5943255 | biostudies-literature
| S-EPMC10561545 | biostudies-literature
| S-EPMC7521772 | biostudies-literature
| S-EPMC7194560 | biostudies-literature
| S-EPMC9781114 | biostudies-literature